Dentsply Sirona: Another Episode Of An Anticipated Recovery

The Value InvestorInvesting Group LeaderFollow5ShareSavePlay(9min)CommentsSummaryDENTSPLY SIRONA trades at historic lows after years of stagnation, underperformance, and failed growth initiatives.DENTSPLY's 2025 outlook projects further declines, with sales guided to $3.50–$3.60B and adjusted EPS to $1.40–$1.50, despite aggressive $120M cost-saving plans.Dividend suspension and new management signal a shift toward debt reduction and operational turnaround, but tangible recovery remains elusive for 2026.Valuation is compelling at 6–7x adjusted earnings, but execution risk is high and the investment case is speculative.Looking for more investing ideas like this one? Get them exclusively at Value In Corporate Events. Learn More » FreshSplash/E+ via Getty Images Investors in DENTSPLY SIRONA (XRAY) have lost their teeth in recent years, as the share price development is a testament to that. Currently trading in the low-teens, the all-time-highs seen around the $60 mark in both 2017 andThis article was written byThe Value Investor27.74K FollowersFollowThe Value Investor has a Master of Science with specialization in financial markets and a decade of experience tracking companies via catalytic company events. As the leader of the investing group Value In Corporate Events they provide members with opportunities to capitalize on IPOs, mergers & acquisitions, earnings reports and changes in corporate capital allocation. Coverage includes 10 major events a month with an eye towards finding the best opportunities. Learn more.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.